Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-56142060
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-56142060 is the primary active metabolite of apalutamide, which is a small molecule androgen receptor antagonist developed for the treatment of prostate cancer. It is formed via metabolic conversion following oral administration of apalutamide. Like the parent compound, JNJ-56142060 acts as an androgen receptor antagonist and plays an important role in mediating the therapeutic effect of apalutamide. Both apalutamide and JNJ-56142060 induce CYP3A4 in human hepatocytes and have been studied for their pharmacokinetic and pharmacodynamic properties in castration-resistant prostate cancer.
- Other names
- M3M-3M 3
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on JNJ-56142060.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-56142060.